Company: GNMSF
Filing Date: 2025-02-12
Form Type: 20-F
Source: 0001558370-25-000846
Chunk: 167

Company: GENMAB A/S
Filing Date: 2025-02-12
Form: 20-F
Item: Item 16K
Chunk 167
---
6-K on February 12, 2025                           
  EX-101. DEF      Inline XBRL Taxonomy Extension Definition Linkbase Document        Incorporated by reference to Exhibit 101. DEF to the Registrant’s report furnished to the SEC on Form 6-K on February 12, 2025                           
  EX-101. LAB      Inline XBRL Taxonomy Extension Labels Linkbase Document            Incorporated by reference to Exhibit 101. LAB to the Registrant’s report furnished to the SEC on Form 6-K on February 12, 2025                           
  EX-101. PRE      Inline XBRL Taxonomy Extension Presentation Linkbase Document      Incorporated by reference to Exhibit 101. PRE to the Registrant’s report furnished to the SEC on Form 6-K on February 12, 2025                           
 ───────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  Portions of this exhibit, marked by brackets, have been omitted pursuant to Instruction 4(a) to Exhibits to Form 20-F because they are both (i) not material and (ii) include information of the ...  

* Certain of the information included within Exhibit 15.2, which is provided pursuant to Rule 12b-23(a) of the Securities Exchange Act of 1934, as amended, is incorporated by reference in this Form 20-F, as specified elsewhere in this Form 20-F. With the exception of the items and pages so specified, the Annual Report 2024 is not deemed to be filed as part of this Annual Report on Form 20-F.

Table of Contents

SIGNATURES

The Registrant hereby certifies that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this Annual Report on its behalf.

  Genmab A/S                                                           
  /s/ Jan G. van de Winkel                                             
  Name:                         Jan G. van de Winkel                   
  Title:                        President and Chief Executive Officer  

Dated: February 12, 2025

Table of Contents

Report of Independent Registered Public Accounting Firm

To theShareholders and Board of Directors of Genmab A/S

Opinions on the Financial Statements and Internal Control over Financial Reporting

We have audited the accompanying consolidated balance sheet of Genmab A/S and its subsidiaries (the “ Company”) as of December 31,